Zacks Research Expects Weaker Earnings for Cooper Companies

The Cooper Companies, Inc. (NASDAQ:COO) – Research analysts at Zacks Research reduced their Q2 2025 EPS estimates for Cooper Companies in a research note issued to investors on Thursday, March 27th. Zacks Research analyst I. Bandyopadhyay now expects that the medical device company will post earnings of $0.93 per share for the quarter, down from their prior estimate of $0.94. The consensus estimate for Cooper Companies’ current full-year earnings is $3.98 per share. Zacks Research also issued estimates for Cooper Companies’ Q3 2026 earnings at $1.16 EPS, Q4 2026 earnings at $1.20 EPS, Q1 2027 earnings at $1.10 EPS and FY2027 earnings at $4.85 EPS.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, March 6th. The medical device company reported $0.92 EPS for the quarter, hitting analysts’ consensus estimates of $0.92. Cooper Companies had a return on equity of 9.38% and a net margin of 10.07%. The company had revenue of $964.70 million during the quarter, compared to analyst estimates of $981.25 million.

A number of other equities research analysts also recently weighed in on COO. Piper Sandler reiterated an “overweight” rating and set a $115.00 price target (down previously from $120.00) on shares of Cooper Companies in a research note on Friday, March 7th. Wells Fargo & Company increased their price target on shares of Cooper Companies from $115.00 to $118.00 and gave the stock an “overweight” rating in a research report on Friday, December 6th. Stifel Nicolaus dropped their target price on Cooper Companies from $115.00 to $105.00 and set a “buy” rating for the company in a report on Friday, March 7th. BNP Paribas upgraded Cooper Companies to a “hold” rating in a research report on Thursday, March 13th. Finally, Needham & Company LLC restated a “hold” rating on shares of Cooper Companies in a research note on Friday, March 7th. Four analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat.com, Cooper Companies presently has a consensus rating of “Moderate Buy” and an average target price of $110.25.

Cooper Companies Trading Down 1.4 %

Cooper Companies stock opened at $83.77 on Monday. Cooper Companies has a 12 month low of $77.05 and a 12 month high of $112.38. The stock has a market cap of $16.75 billion, a price-to-earnings ratio of 42.96, a price-to-earnings-growth ratio of 2.25 and a beta of 1.02. The business has a 50 day moving average price of $89.33 and a two-hundred day moving average price of $97.21. The company has a quick ratio of 1.12, a current ratio of 1.91 and a debt-to-equity ratio of 0.32.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the stock. Fulton Bank N.A. boosted its holdings in Cooper Companies by 3.0% during the fourth quarter. Fulton Bank N.A. now owns 3,718 shares of the medical device company’s stock worth $342,000 after buying an additional 109 shares during the last quarter. Covestor Ltd boosted its position in shares of Cooper Companies by 35.5% during the fourth quarter. Covestor Ltd now owns 458 shares of the medical device company’s stock worth $42,000 after purchasing an additional 120 shares in the last quarter. Shell Asset Management Co. grew its holdings in shares of Cooper Companies by 15.5% in the 4th quarter. Shell Asset Management Co. now owns 946 shares of the medical device company’s stock valued at $87,000 after buying an additional 127 shares during the period. Torray Investment Partners LLC raised its stake in Cooper Companies by 0.8% during the 4th quarter. Torray Investment Partners LLC now owns 16,190 shares of the medical device company’s stock worth $1,488,000 after buying an additional 132 shares during the period. Finally, Mather Group LLC. grew its stake in Cooper Companies by 7.4% in the fourth quarter. Mather Group LLC. now owns 1,926 shares of the medical device company’s stock valued at $177,000 after acquiring an additional 133 shares during the period. Institutional investors and hedge funds own 24.39% of the company’s stock.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.